Key clinical trials of odevixibat (all sponsored by Albireo Pharma, Inc.)

Drug(s)	Indication	Phase	Status	Location(s)	Identifier
Odevixibat, placebo	PFIC (type 1 or 2)	III	Completed	Multinational	NCT03566238; PEDFIC 1; EudraCT2017-002338-21
Odevixibat	PFIC (any type)	III	Recruiting	Multinational	NCT03659916; PEDFIC 2; EudraCT2017-002325-38
Odevixibat, placebo	Alagille syndrome	III	Recruiting	Multinational	NCT04674761; ASSERT; EudraCT2020-004011-28
Odevixibat, placebo	Biliary atresia	III	Recruiting	Multinational	NCT04336722; BOLD; EudraCT2019-003807-37
Odevixibat	Cholestasis	II	Completed	Europe	NCT02630875; EudraCT2015-001157-32

PFIC progressive familial intrahepatic cholestasis